Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

Texas Attorney General Ken Paxton's office said on Thursday it had sued insulin makers Eli Lilly, Novo Nordisk and Sanofi.

“Its patent will expire next year, and it will be available as a generic and I will introduce it to the entire public health ...

Ken Paxton accuses the three big insulin manufacturers of conspiring with the three largest pharmacy companies to overcharge patients hundreds of dollars per dose while raking in sizable profits.

The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...

Novo Nordisk A/S Sponsored ADR Class B (NVO) is currently at $115.65, down $0.83 or 0.71% --Would be lowest close since Feb. 2, 2024, when it closed at $113.70 --Currently down six consecutive days; ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...

Eli Lilly and Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the US, ...

The U.S. Food and Drug Administration said Eli Lilly's diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in expanding ...

Compounded versions of popular weight-loss drugs attracted telehealth companies that marketed services to connect patients with healthcare providers.

BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, which is growing market ...